Establishment of a mouse xenograft model of metastatic adrenocortical carcinoma
Metrics: PDF 629 views | HTML 1395 views | ?
Aurélie Morin1,2, Carmen Ruggiero3,4, Estelle Robidel1,2, Mabrouka Doghman-Bouguerra3,4, Atze T. Das5, Rémy Castellano6, Emmanuelle Josselin6, Judith Favier1,2 and Enzo Lalli3,4
1Université Paris Descartes, Sorbonne Paris Cité, Paris, France
2Inserm UMR970, Paris Cardiovascular Research Centre, Paris, France
3Université Côte d’Azur, Valbonne, Sophia Antipolis, France
4Institut de Pharmacologie Moléculaire et Cellulaire, Valbonne, Sophia Antipolis, France
5Laboratory of Experimental Virology, Department of Medical Microbiology, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands
6Aix Marseille University, CNRS, INSERM, Institut Paoli-Calmettes, CRCM, Marseille, France
Enzo Lalli, email: email@example.com
Keywords: adrenal cortex, cancer, cell lines, mouse models, xenografts
Abbreviations: ACC, adrenocortical carcinoma; EMT, epithelial-mesenchymal transition; GFP, green fluorescent protein; HES, hematoxylin-eosin-safran; SF-1, Steroidogenic Factor 1
Received: December 08, 2016 Accepted: March 15, 2017 Published: April 07, 2017
Adrenocortical carcinoma is a rare neoplasm with a poor prognosis. Very important advances have been made in the identification of the genetic determinants of adrenocortical carcinoma pathogenesis but our understanding is still limited about the mechanisms that determine cancer spread and metastasis. One major problem hindering preclinical experimentation for new therapies for adrenocortical carcinoma is represented by the lack of suitable animal models for metastatic disease. With the aim to overcome these limitations, in this study we tested several protocols in order to establish a mouse xenograft model of metastatic adrenocortical carcinoma. The most efficient method, based upon intrasplenic injection followed by splenectomy, produced metastases with high efficiency, whose development could be followed over time by bioluminescence measurements. We expect that the availability of this model will greatly improve the possibilities for preclinical testing of new treatments for advanced-stage disease.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.